In a phase 3 trial, the combination of AFP and AFP-L3 showed a sensitivity and specificity of 79% and 87%, respectively, for the detection of HCC in a cohort where 74% of patients were diagnosed with early-stage HCC (13). This evidence concerns the gene AFP and hepatocellular carcinoma.